Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
SAN FRANCISCO, April 05, 2018 -- Hagens Berman Sobol Shapiro LLP alerts investors in Solid Biosciences, Inc. (NASDAQ:SLDB) to the May 29, 2018 Lead Plaintiff deadline in the securities class action pending in the United States District Court for the District of Massachusetts. If you purchased Solid Biosciences securities pursuant and/or traceable to its January 25, 2018 initial public offering and/or on the open market between January 25, 2018 and March 14, 2018 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information, visit:
https://www.hbsslaw.com/cases/SLDB
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing
Defendants conducted an initial public offering of Solid Biosciences on or about January 25, 2018. In this IPO, the Company sold approximately 7 million shares at $16 per share to investors.
On March 15, 2018, Defendants announced the U.S. Food and Drug Administration placed a clinical hold on the Company’s Phase 1/2 trial assessing its SGT-001 drug in patients with Duchenne muscular dystrophy. This news drove the price of Solid Biosciences shares down $16.99, or about 65%, to close at $9.32.
The Motley Fool later reported that just prior to the IPO, a prominent researcher left its board because of risks associated with the drug delivery method for Solid Biosciences’ SGT-001 drug.
“We’re focused on investors’ losses and Defendants’ disclosures about internal concerns over the safety of the SGT-001 delivery method leading up to- and after- the IPO,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Solid Biosciences should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 70+ attorneys in 11 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000
